Issue 5/2023
Kalaidzhiev, P., Konstantinova, M., Yakov, S.
Cardiology Clinic at the «Tsaritsa Joanna – ISUL» UMBAL, Medical University – Sofia
Covid-19 infection activates thrombosis in several ways and increases the risk of thromboembolic events. Many clinical trials are investigating whether anticoagulant or antiplatelet therapy should be added for prophylaxis. Data suggest that antiplatelet agents are not recommended for the prevention of thromboembolism in patients with Covid-19. The prophylactic dose of anticoagulant is superior to the therapeutic dose in terms of efficacy and safety in hospitalized patients. Low molecular weight heparins and unfractionated heparin in hospitalized patients are preferred. Oral anticoagulant prophylaxis is useful after hospital discharge, especially in those with high cardiovascular risk and increased risk of deep vein thrombosis.
Address for correspondence:
Кalaidjiev, P.
Clinic of Cardiology,
Hospital „Queen Joanna“, ISUL – Sofia
8, „Bialo more“, Str.
1527, Sofia